Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | STAT1 | P42224 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | GUSB | P08236 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 3/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424060 | 0.88 | MAPT (0.70) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL24075261 | 0.84 | RAB9A (0.73) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL6124304 | 0.83 | NPC1 (0.61) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL3336231 | 0.83 | NPC1 (0.62) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL3541175 | 0.82 | MAPT (0.79) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL3333868 | 0.82 | KDM4E (0.67) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL10175464 | 0.82 | CYP11B1 (0.79) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL8054731 | 0.82 | MAPT (0.67) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL21087331 | 0.81 | NPC1 (0.60) | MAPTRAB9AHPGDKDM4ENPC1 | |
| SCHEMBL16499476 | 0.81 | ALDH1A1 (0.65) | MAPTRAB9AHPGDKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662526-B2 | Photoconductors | XEROX CORPORATION (US) | 2010-02-16 | — | — | US | claimed |
| US-20080274418-A1 | Photoconductors | XEROX CORPORATION | 2008-11-06 | — | — | US | claimed |
| US-8653282-B2 | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | MAPT 4255/4885RAB9A 2130/4885HPGD 601/4885 |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | DPYD, TYMS, DHFR | MAPT 3575/4885RAB9A 1919/4885HPGD 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.